Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Allergan’s results miss on two fronts

Wednesday, November 2, 2016 8:29
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Botox maker Allergan PLC (NYSE:AGN) suffered another minor melt-down as third quarter results missed forecasts and it was cautious with its full year prediction.

Revenues of US$3.32bn, up 4.4%, came in some US$400mln shy of forecasts while earnings undershot by a long way at US$3.32 per share against a consensus US$3.56.

The Dublin-based group blamed Asacol for ulcerative colitis and Alzheimer’s treatment Namenda for the lower than expected earnings.

Shares have dropped by a third since a merger with Pfizer was scrapped in April and they fell a further 3% today to US$202.32.

For 2016 overall, Allergan forecast eps between $13.30 to $13.50 and revenues of $14.45bn and $14.65bn, both of which were below prior consensus targets.

Brent Saunders chief executive, remained upbeat saying company was aiming to end the year with “strong momentum.”

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.